Autoimmune Disease Therapeutics Market Global Industry Analysis, Size, Share, Growth, Industry Insights, Forecast, 2025

According to the report, the global autoimmune disease therapeutics market accounted for $109.83 billion in 2017 and is estimated to garner $153.32 billion by 2025, registering a CAGR of 4.2% from 2018 to 2025.

Increase in adoption of autoimmune disease therapeutics, surge in wide availability of advanced therapeutics, and rise in number of research and development activities drive the growth in the market. However, high initial costs related to advanced therapeutics restrain the market growth. On the other hand, strong presence of pipeline drugs and opportunities in emerging economies create new pathways in the industry.

Request Sample Report at: https://www.alliedmarketresearch.com/request-sample/5185

The global autoimmune disease therapeutics market is divided into drug class, indication, sales channel, and geography. On the basis of drug class, the market is segmented into anti-inflammatory, antihyperglycemics, NSAIDs, interferons, and others. The anti-inflammatory segment held the largest share in 2017, contributing more than half of the total market share. Moreover, the segment is expected to register the fastest CAGR of 5.3% during the forecast period.

Leading market players

Leading market players analyzed in the research include Abbott Laboratories, Amgen Inc., AbbVie Inc.,

Bristol-Myers Squibb Company, AstraZeneca plc., Johnson & Johnson, F. Hoffmann-La Roche AG, Pfizer Inc., Novartis AG, and UCB S.A.

Drug stores & retail pharmacies to maintain its dominant position by 2025

Drug stores & retail pharmacies accounted for nearly three-fifths of the total share in 2017 and will maintain its dominant position by 2025, owing to ease in availability offered by them and presence of large number of stores. However, online stores would grow at the fastest rate, registering a CAGR of 6.8% from 2018 to 2025, owing to rise in preference for online channels and advantages such as less expenses, enhanced convenience, and easy access to reviews of other patients.

Rheumatic disease segment to maintain its dominant share by 2025

Based on indication, rheumatic disease segment contributed nearly half of the total market share in 2017 and will maintain its dominant share by 2025. Moreover, this segment would register the highest growth rate, with a CAGR of 5.2% from 2018 to 2025. This is due to increase in prevalence, surge in R&D activities, and availability of advanced therapeutics. The report also analyzes type 1 diabetes, multiple sclerosis, inflammatory bowel disease, and others.

For Purchase Enquiry: https://www.alliedmarketresearch.com/purchase-enquiry/5185

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
USA/Canada (Toll Free): +1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
Life Science Market: https://www.alliedmarketresearch.com/reports-store/life-sciences
Follow Us on LinkedIn: https://www.linkedin.com/company/allied-market-research

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.